RarePlex® PD-L1 CTC Panel Kit

RarePlex – Staining Kits
Panel Kits – Enumeration | ARv7 | HER2/ER | PD-L1
Developer Kits – 405/488
View Datafiles


RarePlex PD-L1 CTC Panel Kit

RareCyte’s programmed death ligand 1 (PD-L1) circulating tumor cell assay provides highly accurate, repeatable, and precise results for circulating tumor cell count and PD-L1 biomarker expression, and is suitable for use in large, multi-center clinical trials. The assay includes processing blood to slides with the AccuCyte® Sample Preparation System followed by staining with the RarePlex 0912-VB PD-L1 CTC Panel Kit and imaging on a CyteFinder® Instrument. Machine learning enabled analysis and scoring maximizes reviewer concordance.

This PD-L1 assay is deployed on RareCyte’s circulating tumor cell analysis platform with:

  • Simple processing of blood to slides for sample banking
  • Convenient pause points in workflow enable sample control and transport
  • Flexibility in sample handling – processing and analysis may be performed at the same site or at a separate clinical research laboratory when desired
  • Extensive validation and highly automated process yield accurate and highly reproducible results
  • Worldwide network of contract research organizations (CROs) to support global clinical trials
SW900 (PD-L1 high), H1650 (PD-L1 low), and HAP-1 (PD-L1 negative) cell lines are shown. The top row represents a merge image where Nuclei = blue, CD45 = green, and CK/EpCAM = magenta. The PD-L1 localization in the bottom row matches expected expression levels.
Scale bar represents 10μm.
TALK TO AN EXPERT


Clinical lung cancer sample stained with the PD-L1 CTC Panel Kit. Merge represents a composite image of CK/EpCAM, Nuclei, and CD45.
Scale bar represents 10μm.
Distribution of PD-L1 MFI for mCTC across the 5 slide replicates per cell line for stainer run 1 (left), 2, (center), and 3 (right). Threshold dotted line at MFI=500 is used to determine biomarker expression status on a per-cell basis.


VIEW DATAFILE